Pneumocystis pneumonia in COVID-19 patients: A comprehensive review

[1]  Brendan R. Jackson,et al.  Coronavirus Disease 2019–Associated Invasive Fungal Infection , 2021, Open forum infectious diseases.

[2]  G. Messina,et al.  Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience , 2021, International journal of environmental research and public health.

[3]  A. Giacomelli,et al.  Invasive Fungal Infections Complicating COVID-19: A Narrative Review , 2021, Journal of fungi.

[4]  B. Soeprijanto,et al.  Concurrent COVID-19 and Pneumocystis jirovecii pneumonia: The importance of radiological diagnostic and HIV testing , 2021, Radiology Case Reports.

[5]  K. Agarwal,et al.  Co-infection with SARS-CoV-2 and Pneumocystis jirovecii in liver transplant recipients: A double whammy , 2021, Journal of Liver Transplantation.

[6]  J. Tran van Nhieu,et al.  Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19 , 2021, Critical Care.

[7]  A. Goodman,et al.  Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity , 2021, Clinical Infection in Practice.

[8]  F. Schneider,et al.  Detection of Pneumocystis jirovecii in Patients with Severe COVID-19: Diagnostic and Therapeutic Challenges , 2021, Journal of fungi.

[9]  B. Saha,et al.  Narrative review of the relationship between COVID-19 and PJP: does it represent coinfection or colonization? , 2021, Infection.

[10]  D. Barouch,et al.  Co-infection with coronavirus disease 2019, previously undiagnosed human immunodeficiency virus, Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonitis, with possible immune reconstitution inflammatory syndrome , 2021, IDCases.

[11]  I. I. Jeican,et al.  COVID-19 and Pneumocystis jirovecii Pulmonary Coinfection—The First Case Confirmed through Autopsy , 2021, Medicina.

[12]  N. Shen,et al.  Successful treatment of a kidney transplant patient with COVID-19 and late-onset Pneumocystis jirovecii pneumonia , 2021, Annals of Clinical Microbiology and Antimicrobials.

[13]  H. Masur,et al.  Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Vargas,et al.  Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19 , 2021, Infectious diseases.

[15]  C. Koegelenberg,et al.  The diagnostic challenge of pneumocystis pneumonia and COVID‐19 co‐infection in HIV , 2021, Respirology case reports.

[16]  H. Badali,et al.  The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis , 2021, Mycoses.

[17]  E. Longchampt,et al.  COVID-19 and Pneumocystis jirovecii pneumonia: Back to the basics , 2021, Respiratory Medicine and Research.

[18]  P. Manckoundia,et al.  Not COVID-19, Don’t Overlook Pneumocystis in Patients on Gefitinib! , 2021, Current oncology.

[19]  A. Loundou,et al.  CD169 and CD64 could help differentiate bacterial from CoVID‐19 or other viral infections in the Emergency Department , 2021, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[20]  J. Parr,et al.  Pneumocystis and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Case Report and Review of an Emerging Diagnostic Dilemma , 2020, Open forum infectious diseases.

[21]  Heleniak,et al.  Coinfection of COVID -19 and pneumocystosis in a patient after kidney transplantation , 2021 .

[22]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[23]  B. Mégarbane,et al.  The presence of Pneumocystis jirovecii in critically ill patients with COVID-19 , 2020, Journal of Infection.

[24]  A. Remesal,et al.  Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report , 2020, Modern rheumatology case reports.

[25]  Xiao Lv,et al.  The changes of the peripheral CD4+ lymphocytes and inflammatory cytokines in Patients with COVID-19 , 2020, PloS one.

[26]  Chih-Cheng Lai,et al.  COVID-19 associated with pulmonary aspergillosis: A literature review , 2020, Journal of Microbiology, Immunology and Infection.

[27]  A. Fekkar,et al.  COVID-19–related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis , 2020, American journal of respiratory and critical care medicine.

[28]  S. Asghari,et al.  Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: diagnostic role of inflammatory indications in determining the severity of illness , 2020, BMC Infectious Diseases.

[29]  F. Scolari,et al.  Pneumocystis jirevocii and SARS-CoV-2 Co-Infection: A Common Feature in Transplant Recipients? , 2020, Vaccines.

[30]  A. Borghetti,et al.  People living with HIV in the CoVid-19 era: a case report. , 2020, AIDS research and human retroviruses.

[31]  K. Liang,et al.  The Diagnostic Trap Occurred in Two COVID-19 Cases Combined Pneumocystis Pneumonia in Patient with AIDS , 2020, Research square.

[32]  Pavan Bhat,et al.  COVID-19 and PCP co-infection in a severely immunocompromised 25 year-old patient , 2020, International Journal of Infectious Diseases.

[33]  Pavan Bhat,et al.  Concurrent COVID-19 and Pneumocystis jirovecii pneumonia in a severely immunocompromised 25-year-old patient , 2020, International Journal of Infectious Diseases.

[34]  S. Leptihn,et al.  Secondary Bacterial Infections in Patients With Viral Pneumonia , 2020, Frontiers in Medicine.

[35]  A. J. Agulló,et al.  Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS , 2020, Intensive Care Medicine.

[36]  P. White,et al.  A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  S. Becker,et al.  Pneumocystis Jirovecii Pneumonia and SARS-CoV-2 Co-Infection in newly diagnosed HIV-1 infection. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  T. Boekhout,et al.  Oropharyngeal candidiasis in hospitalised COVID‐19 patients from Iran: Species identification and antifungal susceptibility pattern , 2020, Mycoses.

[39]  A. Fekkar,et al.  Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19 , 2020, Clinical Microbiology and Infection.

[40]  Russell E. Lewis,et al.  Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion , 2020, Intensive Care Medicine.

[41]  Wei Sun,et al.  A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab , 2020, Clinical Rheumatology.

[42]  R. Simons,et al.  COVID-19 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV , 2020, AIDS.

[43]  N. Van Regenmortel,et al.  COVID-19-associated invasive pulmonary aspergillosis , 2020, Annals of Intensive Care.

[44]  Xiao Yu,et al.  Fungal antigenemia in patients with severe Coronavirus disease 2019 (COVID-19): The facts and challenges , 2020, Journal of Microbiology, Immunology and Infection.

[45]  B. Mégarbane,et al.  Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19 , 2020, The Lancet Respiratory Medicine.

[46]  D. Berg,et al.  A Case of COVID-19 and Pneumocystis jirovecii Coinfection , 2020, American journal of respiratory and critical care medicine.

[47]  P. van Wijngaarden,et al.  COVID-19–associated Pulmonary Aspergillosis , 2020, American journal of respiratory and critical care medicine.

[48]  G. Cooke,et al.  Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  C. Koegelenberg,et al.  HIV and SARS-CoV-2 co-infection: The diagnostic challenges of dual pandemics. , 2020, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[50]  M. Hallek,et al.  COVID‐19 associated pulmonary aspergillosis , 2020, Mycoses.

[51]  Y. Shoenfeld,et al.  On the molecular determinants of the SARS-CoV-2 attack , 2020, Clinical Immunology.

[52]  Felipe García,et al.  COVID-19 in patients with HIV: clinical case series , 2020, The Lancet HIV.

[53]  Yuzhou Gu,et al.  Coinfection of Influenza Virus and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) , 2020, The Pediatric infectious disease journal.

[54]  Zhiguang Zhou,et al.  Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? , 2020, Journal of Autoimmunity.

[55]  B. Mégarbane,et al.  Do COVID-19 patients admitted to the ICU require anti-Pneumocystis jirovecii prophylaxis? , 2020, medRxiv.

[56]  Giuseppe Citerio,et al.  Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) , 2020, Intensive Care Medicine.

[57]  Tara C Smith,et al.  Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS–CoV-2/COVID-19 , 2020, mBio.

[58]  T. Singhal.  A Review of Coronavirus Disease-2019 (COVID-19) , 2020, The Indian Journal of Pediatrics.

[59]  P. Horby,et al.  A novel coronavirus outbreak of global health concern - Comment - Correction , 2020 .

[60]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[61]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[62]  Heshui Shi,et al.  Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet Infectious Diseases.

[63]  Long Jiang Zhang,et al.  Coronavirus Disease 2019 (COVID-19): A Perspective from China , 2020, Radiology.

[64]  P. Horby,et al.  A novel coronavirus outbreak of global health concern , 2020, The Lancet.

[65]  Weisi Guo.  The Diagnostic Trap Occurred in Two COVID-19 Cases Combined Pneumocystis Pneumonia in Patient with AIDS , 2020 .

[66]  S. Brusca,et al.  [Simultaneous diagnosis and favorable evolution of infection with Pneumocystis jirovecii, SARS-CoV-2 and advanced HIV]. , 2020, Medicina.

[67]  J. Perfect,et al.  Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  Felipe García,et al.  Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients , 2019, Expert review of anti-infective therapy.

[69]  A. Panarra,et al.  Pneumocystosis pneumonia: A comparison study between HIV and non-HIV immunocompromised patients. , 2019, Pulmonology.

[70]  C. Wennerås,et al.  Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-β-D-glucan in HIV-infected patients: a retrospective case control study , 2019, BMC Infectious Diseases.

[71]  D. Beuningen,et al.  Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality , 2018, Journal of Critical Care.

[72]  P. White,et al.  Therapy and Management of Pneumocystis jirovecii Infection , 2018, Journal of fungi.

[73]  E. Andrinopoulou,et al.  Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. , 2018, The Lancet. Respiratory medicine.

[74]  M. Hoenigl,et al.  Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia , 2018, Respiration.

[75]  S. Bretagne,et al.  Pneumocystis jirovecii detection in asymptomatic patients: what does its natural history tell us? , 2017, F1000Research.

[76]  É. Azoulay,et al.  Pneumocystis jirovecii Pneumonia in Patients with or without AIDS, France , 2014, Emerging infectious diseases.

[77]  J. Steinmann,et al.  ADVANCES IN DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS ( U BINDER , SECTION EDITOR ) Update on Diagnosis of Pneumocystis Pulmonary Infections , 2014 .

[78]  John T Brooks,et al.  Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  S. Le Gal,et al.  Combined Quantification of Pulmonary Pneumocystis jirovecii DNA and Serum (1→3)-β-d-Glucan for Differential Diagnosis of Pneumocystis Pneumonia and Pneumocystis Colonization , 2013, Journal of Clinical Microbiology.

[80]  M. Falagas,et al.  Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[81]  C. Meyer,et al.  Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. , 2012, AJR. American journal of roentgenology.

[82]  S. Ichiyama,et al.  Quantitative real-time PCR and the (1→3)-β-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[83]  A. Morris,et al.  Colonization by Pneumocystis jirovecii and Its Role in Disease , 2012, Clinical Microbiology Reviews.

[84]  J. Chmiel,et al.  AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study , 2010, AIDS.

[85]  E. Dei‐Cas,et al.  Pneumocystis infection in humans: diagnosis and treatment , 2010, Expert review of anti-infective therapy.

[86]  V. Saegeman,et al.  Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital. , 2010, Medical mycology.

[87]  E. Vidal-Petiot,et al.  Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection , 2008, Critical care.

[88]  C. Lacroix,et al.  Analysis of Underlying Diseases and Prognosis Factors Associated with Pneumocystis carinii Pneumonia in Immunocompromised HIV-Negative Patients , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[89]  A. Limper,et al.  Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. , 1998, Seminars in respiratory infections.

[90]  T. F. Smith,et al.  Pneumocystis carinii Pneumonia: Differences in Lung Parasite Number and Inflammation in Patients with and without AIDS , 1989 .

[91]  D. White,et al.  Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. , 1988, The American review of respiratory disease.